Skip to main content

Table 1 Reclassification table with the results for intermediate-risk patients according to the ACR/EULAR 2010 RA classification criteria and for all patients

From: A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis

 

Number of patients according to ACR/EULAR 2010 RA classification criteria

Number of patients reclassified as high risk

Number of patients reclassified as low risk

Combined sensitivity: RA-2010 criteria + new test

Combined specificity: RA-2010 criteria + new test

(A) Add-on test for all patients

B cell test

   

0.85

0.69

High risk

243

243

0

  

Intermediate risk

263

75 (29 %)

188 (71 %)

  

Low risk

46

13 (28 %)

33 (72 %)

  

IL-6 test

   

0.89

0.41

High risk

243

243

0

  

Intermediate risk

263

146 (56 %)

117 (44 %)

  

Low risk

46

26 (57 %)

20 (43 %)

  

Magnetic resonance imaging

   

0.96

0.46

High risk

243

243

0

  

Intermediate risk

263

154 (59 %)

109 (41 %)

  

Low risk

46

26 (59 %)

20 (41 %)

  

Genetic assay test

   

0.77

0.66

High risk

243

243

0

  

Intermediate risk

263

64 (24 %)

199 (76 %)

  

Low risk

46

11 (24 %)

35 (76 %)

  

(B) Add-on test for intermediate-risk patients

B cell test

   

0.81

0.71

High-risk

243

243

0

  

Intermediate risk

263

75 (29 %)

188 (71 %)

  

Low risk

46

0

46

  

IL-6 test

   

0.85

0.46

High risk

243

243

0

  

Intermediate risk

263

146 (56 %)

117 (44 %)

  

Low risk

46

0

46

  

MRI

   

0.91

0.51

High risk

243

243

0

  

Intermediate risk

263

154 (59 %)

109 (41 %)

  

Low risk

46

0

46

  

Genetic assay test

   

0.75

0.67

High risk

243

243

0

  

Intermediate risk

263

64 (24 %)

199 (76 %)

  

Low risk

46

0

46

  
  1. Combined sensitivity = sensitivity of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis (RA) classification criteria + sensitivity of the new test. Combined specificity = specificity of ACR/EULAR 2010 RA classification criteria + specificity of the new test.